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Abstract
Despite inducing very low IFN-c response and highly attenuated in vivo, infection of mice with phosphoglycan (PG)
deficient Leishmania major (lpg2-) induces protection against virulent L. major challenge. Here, we show that mice infected
with lpg2- L. major generate Leishmania-specific memory T cells. However, in vitro and in vivo proliferation, IL-10 and IFN-c
production by lpg2- induced memory cells were impaired in comparison to those induced by wild type (WT) parasites.
Interestingly, TNF recall response was comparable to WT infected mice. Despite the impaired proliferation and IFN-c
response, lpg2- infected mice were protected against virulent L. major challenge and their T cells mediated efficient
infection-induced immunity. In vivo depletion and neutralization studies with mAbs demonstrated that lpg2- L. major-
induced resistance was strongly dependent on IFN-c, but independent of TNF and CD8+ T cells. Collectively, these data
show that the effectiveness of secondary anti-Leishmania immunity depends on the quality (and not the magnitude) of IFN-
c response. These observations provide further support for consideration of lpg2- L. major as a live-attenuated candidate for
leishmanization in humans since it protects strongly against virulent challenge, without inducing pathology in infected
animals.
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Introduction
Leishmaniasis is a serious global health problem that affects
millions of people worldwide, especially in developing tropical and
subtropical countries. According to WHO estimate, about 2
million new cases occur every year and over 12 million people are
presently infected [1]. In India, around 60,000 deaths were
reported in 1999 due to visceral leishmaniasis, but the actual
number is thought to be even much higher [2]. A most recent
report estimated that 20,000–40,000 leishmaniasis deaths occur
per year and most of these deaths occur in only six countries [3].
Various forms of pentavalent antimonial components are used for
treatment of human leishmaniasis, but treatment failures and drug
resistances are common [4,5]. Hence, there is urgent need for new
drugs as well as the development of effective human vaccines to
prevent the disease. The development of effective vaccine requires
an understanding of the factors that regulate secondary protective
immunity.
Following recovery from primary natural or experimental
infection with L. major, a state of immunity develops that is able
to rapidly protect healed animals (both humans and mice) against
secondary challenge [6]. Such infection-acquired immunity is very
durable and is mediated by IFN-c-producing effector and central
memory-like T cells [7]. Infection-acquired immunity is the
underlying principle behind leishmanization, which is still
practiced in some countries today [8]. However, the significant
morbidity associated with the practice has hampered its use as an
acceptable vaccination strategy. Moreover, because leishmaniza-
tion results in a chronic (latent) infection state, concerns have been
raised of the possibility to full blown infection in immunocom-
promised individuals [9].
An increasing number of parasites lines arising through gene
replacement methods have been described which show some
promise as vaccine candidates in animal studies [10–12]. Among
these, phosphoglycan (PG) deficient L. major (termed lpg22) is of
particular interest because it does not induce pathology even in
immunocompromised mice [13] and persists indefinitely at levels
comparable to WT parasites. Persistence has been associated with
maintenance of infection-acquired immunity [14,15]. Since lpg22
mutant parasites persist without causing any disease even in the
susceptible mice and protects against virulent challenge [12], these
attributes make lpg22 mutants a promising live-attenuated
Leishmania vaccine candidate and have provoked considerable
interests in understanding how it persists and interacts with the
host immune system. An unanswered important question is
whether lpg22 parasites could induce secondary (memory)
immune response comparable to those of WT parasites. Here,
we show that despite significant differences in quantity, the
secondary anti-Leishmania immunity induced by WT and lpg22
parasites are qualitatively similar. These findings further support
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the consideration of lpg22 parasites as live attenuated vaccine
candidate against cutaneous leishmaniasis.
Materials and Methods
Mice
Female C57BL/6 and BALB/c mice 6 to 8-wk-old were
purchased from the Central Animal Care Services (CACS),
University of Manitoba. Female B6.PL-Thy1a/CyJ (Thy1.1) mice
were purchased from Jackson Lab, Bar Harbor, Maine.
Ethics Statement
All mice were kept at the University of Manitoba Central
Animal Care Services (CACS) facility in accordance to the
Canadian Council for Animal Care guidelines. The University of
Manitoba Animal Use Ethics Committee approved all studies
involving animals, including infection, humane endpoints, eutha-
nasia and collection of samples.
Parasites
The origin of wild type (WT) and phosphoglycan deficient
(lpg22) L. major has been previously described [13,16–18].
Parasites were cultured at 26uC in M199 medium (Hyclone,
Logan, UT) supplemented with 10% heat-inactivated FBS, 2 mM
L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (Hy-
clone). For selective growth of lpg22 line, Hygromycin B (20 mg/
ml) was added to the culture media. While in a previous study we
reported the occurrence of lpg22 revertants lacking LPG but
conferring pathology [19], this was not observed in the studies
described here.
Infection Protocol and Parasite Quantification
Stationary phase promastigotes were washed three times,
resuspended in PBS at 108/ml and 50 ml containing 56106 (for
C57BL/6 infections) or 26106 (for BALB/c infections) parasites
was injected into the right or left hind footpad. Lesion sizes were
monitored weekly with Vanier calipers and parasite burden was
determined by limiting dilution assay [20].
Generation of Bone Marrow Derived Dendritic Cells
(BMDCs) and in vitro Infection
Bone marrow cells were isolated from the femur of C57BL/6
mice, seeded in 100615 mm Petri dishes at 26105/ml and
differentiated using recombinant murine GM-CSF (20 ng/ml,
Peprotech, Indianapolis, IN). The culture media were changed
twice on day 3 and on day 6, and on day 7, the non-adherent cells
were collected and assessed for the expression of CD11c, CD40,
CD80, CD86 and MHC class II by flow cytometry. The purity of
DCs was between 85–92% (CD11c+ cells). BMDCs were
incubated with WT parasites for 5 hours at a BMDC to parasite
ratio of 1:10. Thereafter, free parasites were washed away and
infected cells were used in subsequent co-culture experiments.
T cell Purification, 5- (6-) Carboxyfluorescein Diacetate
Succinimidyl Ester (CFSE) Labeling, Adoptive Transfer and
Co-culture Experiments
T cells were purified from the spleens or dLNs of infected or
naive mice by positive selection using CD90.2 coated microbeads
and autoMACS (Auburn, CA) according to the manufacturer’s
suggested protocols and labeled with CFSE dye as described
previously [21]. Ten to 30 million cells were adoptively transferred
into naı¨ve congenic (Thy1.1) mice by tail vein injection. Recipient
mice were subsequently infected with L. major the next day,
sacrificed at 5, 14 and 21 days post-challenge to assess
proliferation, CD44 and CD62L expression and TNF and IFN-
c production.
In vitro Recall Response, Proliferation and Intracellular
Cytokine Staining
At various times after infection, spleen and dLN cells were
cultured in complete DMEM medium at 46106 cells/ml (1 ml/
well) in 24-well tissue culture plates and stimulated with soluble
Leishmania antigen (SLA, 50 mg/ml) as previously described [22].
After 72 hr, the culture supernatants were collected and stored at
–20uC until assayed for cytokines by ELISA. For proliferation,
CFSE-labeled cells labeled were resuspended at 106/ml, plated
onto 96-well round bottom plates and stimulated with SLA or anti-
CD3 and anti-CD28 as previously described [23] or co-cultured
with L. major-infected BMDCs at T cell:BMDC of 100:1. After 5
days, proliferation was analyzed by flow cytometry. Some cells
were used for intracellular cytokine (IL-4, IL-10, TNF and IFN-c)
staining as previously described [24]. Samples were acquired on a
FACSCanto II flow cytometer (BD Bioscience, Mississauga, ON,
Canada) and analyzed with FlowJo software (TreeStar, Ashland,
OR).
Cytokine ELISAs
The levels of IL-4, IL-10, TNF and IFN-c in the culture
supernatant fluids were determined by sandwich ELISA using
antibody pairs and recombinant cytokine standard (BD Biosci-
ences San Jose, CA) according to the manufacturer’s suggested
protocols.
Treatment with anti-IFN-c, anti-CD8 Monoclonal
Antibody (mAb) and TNFR-Ig in vivo
Mice infected with WT or lpg22 L. major were injected
intraperitoneally with purified anti- IFN-c mAb (XMG1.2,
2 mg/mouse) or 30 mg/kg Embrel, a TNFR2-Ig fusion protein
that inhibits functional activity of murine TNF in vivo [25,26]. The
next day, mice were challenged with L. major and antibody or
fusion protein treatments were continued weekly for additional 2
weeks. In some experiments, mice were treated with anti-CD8
mAb (TIB210, 1 mg/mouse) 1 day before challenge and for
additional 2 weeks (at weekly intervals). This treatment leads to
complete and sustained depletion all CD8+ cells throughout the
treatment period. All mice were sacrificed after 3 weeks to estimate
parasite burden.
Statistical Analysis
Results are shown as the mean 6 SEM. A two-tailed Student’s
t-test was used to compare means of lesion sizes, parasites burden,
and cytokine production from different groups of mice. Signifi-
cance was considered if p#0.05 (*, = p#0.05; **, = p#0.01 and
***, = p#0.001).
Results
lpg22 L. major Parasites Induce Memory T cell Population
in the Susceptible and Resistant Mice
As previously reported [13], lpg22 L. major persists in the footpad
of BALB/c mice without causing any lesion for up to 16 weeks
post-infection (Figure 1A and data not shown). Consistent with
our previous observation [12], spleens and draining lymph nodes
(dLNs) from 13 wk-infected mice contain low but detectable
number of IFN-c-producing cells (Figure 1B, left panel),
following short-term (3 days) in vitro restimulation with SLA.
Phosphoglycans Regulate Immunity to L. major
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Figure 1. lpg22 L. major parasites induce memory T cells in infected BALB/c mice. BALB/c mice were infected with 2 million wild-type (WT)
and lpg22 L. major stationary phase promastigotes and lesion size was monitored weekly with Vernier calipers (A). After 16 wk post-infection,
Phosphoglycans Regulate Immunity to L. major
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Furthermore, CD4+ T cells from lpg2-infected mice (but not those
from naı¨ve mice) proliferated strongly in response to SLA
stimulation in vitro, indicating that parasites-specific memory T
cells are maintained even in the absence of cutaneous lesions
(Figure 1B, right panel).
BALB/c mice do not naturally heal WT L. major infections,
which makes it difficult to compare memory responses following
lpg22 and WT L. major infections in this mouse strain. Therefore,
we utilized C57BL/6 mice to investigate and compare the quality
of memory response following infection with WT and lpg22 L.
major. As shown in Figure 2A and consistent with our previous
report [27], lpg22infected C57BL/6 mice did not develop any
lesion while mice infected with WT parasites developed lesions
that healed by 12 weeks post-infection. Sixteen (16) weeks after
infection, both WT and lpg22 infected C57BL/6 mice contain
comparable numbers of parasites (,1000) in their footpads
(Figure 2B). However, the dLNs (data not shown) and spleens
of mice infected with lpg22 parasites contained significantly less
IFN-c- (Figure 2C), IL-4 and IL-10 (Figure S1A and S1B) -
producing cells and produced less IFN-c (Figure 2D) and IL-10
(Figure 2E) than those from WT L. major-infected mice following
in vitro restimulation with SLA.
Because WT and lpg22 L. major differentially activate infected
dendritic cells [28], we tested whether the impaired IFN-c
response in lpg22 L. major-infected mice was related to suboptimal
antigen presentation following SLA restimulation. Therefore, we
restimulated cells from lpg22 infected mice in vitro with L. major-
infected bone marrow-derived dendritic cells (BMDCs) and
assessed proliferation and IFN-c production. Similar to SLA
stimulation, proliferation and IFN-c production by T cells from
lpg2- infected mice were significantly lower than those from WT-
infected mice (Figure 2F and 2G). Interestingly, the frequency of
TNF-producing T cells from WT and lpg22 infected mice
following in vitro restimulation with infected DCs was comparable
(Figure S2), suggesting that the difference in IFN-c recall
responses was not related to global impairment or reduction in
numbers of Leishmania-specific memory cells in lpg2- infected mice.
Collectively, these results suggest that lpg22 parasites are less
effective in inducing IFN-c-producing memory T cell responses
than WT parasites.
Impaired Proliferation and IFN-c Production by T cells
from lpg22 L. major-infected Mice are Maintained in vivo
To further determine whether the impaired secondary (prolif-
eration and IFN-c production) responses observed in T cells from
lpg22 L. major infected mice are strictly related to T cells and in a
more physiological environment, we adoptively transferred equal
numbers of CFSE-labeled highly enriched T cells from healed WT
and lpg22 L. major-infected or naive Thy1.2 (CD90.2+) mice into
naı¨ve congenic Thy1.1 (CD90.1+) recipients and challenged them
with WT L. major. Challenged mice were sacrificed on days 5, 14
and 21 post-challenge and donor (CD90.2+) T cells from the dLNs
and spleens were assessed for cell proliferation and IFN-c
production by flow cytometry (Figure 3A). At all time points
tested, cells from lpg2-infected mice were less proliferative
(Figure 3B) and produced significantly (p,0.05) less IFN-c
(Figure 3C) in response to virulent L. major challenge than those
from WT-infected mice, suggesting that the defect in memory
responses observed in lpg2-infected mice is strictly related to T
cells.
Quantitative Differences in Memory T cells from WT and
lpg22 L. major-infected Mice
To directly determine whether there are quantitative differ-
ences in numbers of memory T cells in mice infected with WT
and lpg22 parasites, we assessed the expression of CD62L and
CD44 on T (CD3+) cells from WT- and lpg2–infected mice
directly ex vivo by flow cytometry. CD44 is a marker of previous
T cell activation and hence is expressed by all memory T cells
[29] whereas CD62L is a lymph node homing receptor for
lymphocytes, which is downregulated upon lymphocyte activa-
tion. These markers discriminate between central memory-like
T cells (CD44hiCD62Lhi, Tcm) and effector memory-like T cells
(CD44hiCD62Llo, Tem) [24]. Our direct ex vivo results show that
the percentages of CD4+ memory-like T cells (Tcm and/or
Tem populations) in the draining lymph nodes of lpg22infected
mice were much lower than those from WT-infected mice
(Figure 4A).
Next, we used the highly sensitive adoptive transfer studies to
determine whether there were differences in CD62L expression on
proliferating (Leishmania-experienced) donor cells from WT and
lpg22 L. major-infected mice in vivo. At day 14 post-challenge,
donor CD3+ T cells from both groups proliferated and downreg-
ulated their CD62L expression (Figure 4B), although these events
were more pronounced in cells from WT-infected mice. Thus,
despite lower proliferative response, Leishmania-reactive cells from
lpg2-infected mice could downregulate their CD62L expression,
suggesting that they could potentially home to the site of infection
to mediate effector functions.
Infection with lpg22 L. major Protects Against Virulent
Challenge Despite Poor DTH Response
To test whether cells from lpg22infected mice could confer
protection to naı¨ve mice following adoptive transfer, we
challenged WT and lpg2- infected C57BL/6 mice with virulent
WT L. major parasites and after 72 hr, measured delayed-type
hypersensitivity (DTH) response. We found that WT L. major-
infected mice exhibited strong DTH response whereas lpg2-
infected mice did not exhibit any significant DTH response
following challenge (Figure 5A). Interestingly, despite the
impaired proliferation, IFN-c and DTH responses, lpg2-infected
mice displayed comparable protection to WT-infected mice
(Figure 5B). Furthermore, adoptive transfer of highly purified
T cells from both WT and lpg2-infected mice conferred
comparable protection to naı¨ve mice against virulent L. major
challenge (Figure 5C). Taken together, these results indicate
that despite quantitative differences in recall responses, cells
from lpg22infected mice are qualitatively as efficient as those
from WT-L. major-infected mice in mediating secondary
protective immunity.
Protection in lpg22infected Mice is Dependent on IFN-c
but is Independent of CD8+ T cells
We previously showed that infection with lpg22 L. major
induced a strong primary CD8+ T cell proliferation and IFN-c
production [28]. Since CD8+ T cells are important in both
draining lymph node cells and splenocytes from lpg22 infected BALB/c mice were labeled with CFSE, restimulated in vitro with SLA for 5 days,
stained intracellularly for IFN-c and assessed for proliferation by flow cytometry, the numbers showed on dot plots represent percentages in total T
cell population (B). Data presented is a representative of 3 independent experiments with similar results.
doi:10.1371/journal.pone.0066058.g001
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Figure 2. T cells from the spleens of WT and lpg22 infected C57BL/6 mice proliferate and produce IFN-c in response to L. major–
infected DCs. C57BL/6 mice were infected with WT and lpg22 L. major and the kinetics of lesion development and progression was monitored for
over 16 weeks (A). At 16 weeks after infection, infected mice were sacrificed and parasite burden was determined by limiting dilution (B). Spleen cells
were restimulated in vitro with SLA for 72 hr and the frequency of IFN-c-producing cells was determined by flow cytometry (C). The culture
supernatant fluids were assessed for IFN-c (D) and IL-10 (E) by ELISA. In some experiments, CFSE-labeled purified T cells purified from infected mice
were co-cultured for 5 days with L. major–infected BMDCs (T:BMDC = 100:1), stained for surface expression of CD4 and CD8 and intracellularly for IFN-
c and analyzed by flow cytometry. Shown are the percentages of cells that proliferated i.e. diluted CFSE dye (F) and produce IFN-c (G). Data are
presented are representative of 2 independent experiments with similar results.
doi:10.1371/journal.pone.0066058.g002
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primary [23,30] and secondary [31] anti-Leishmania immunity,
we speculated that secondary resistance in lpg2–infected mice
might be dependent on CD8+ T cells. As shown in Figure 6A
and 6B and similar to WT infection, depletion of CD8+ T cells
had no effect on lpg2-induced protection, suggesting that CD8+
T cells are dispensable for both WT and lpg22 L. major-induced
immunity. Because lpg2-infected mice were protected against
secondary L. major challenge despite showing significantly
impaired IFN-c recall response in vitro and in vivo, we investi-
gated whether protection following lpg2-infection is independent
of IFN-c. The data in Figure 6C and 6D show that IFN-c is
stringently required for lpg2-induced protection as neutralization
Figure 3. Impaired proliferative response and IFN-c production by T cells from lpg2-infected mice in vivo. Naı¨ve Thy1.1 (CD90.1) mice
received (by i.v. injection) CFSE-labeled highly purified (.98% pure) T cells from Thy1.2 (CD90.2) mice infected for.16 wk with WT or lpg22 L. major.
Recipient mice were challenged with 26106 WT L. major the next day and sacrificed at indicated times. Splenocytes or dLNs cells were stimulated
with PMA and ionomycin in the presence of Brefeldin A and directly stained with anti-CD3, anti-CD90.2, anti-CD4, anti-CD8, anti-IFN-c antibodies
conjugated with different fluorochromes, gated on CD90.2+ donor population (A) and analyzed for proliferation (B) and IFN-c production (C) by flow
cytometry. Data presented are representative of 2 independent experiments (n = 4–5 mice per group) with similar results.
doi:10.1371/journal.pone.0066058.g003
Phosphoglycans Regulate Immunity to L. major
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of this cytokine by anti-IFN-c mAb completely abrogated the
protection.
Protection in lpg2 L. major-infected Mice is not due to
Intact TNF Production
In addition to IFN-c TNF has been shown to play a critical role
in resistance to L. major [32]. Unlike the impaired IFN-c
Figure 4. Quantitative differences in memory T cells in WT and lpg22 L. major-infected mice. Cells from spleens and dLNs from 20 weeks
wide-type and lpg2–infected mice were stained with anti-CD3, anti-CD4, anti-CD62L and anti-CD44 antibodies conjugated with different
fluorochromes and analyzed by flow cytometry. Expression of CD44 and CD62L on T cell subsets (A). Naı¨ve Thy1.1 mice that received CFSE-labeled
spleen cells from mice infected with WT or lpg2- L. major for.16 wk were challenged 24 hr after cell transfer and sacrificed on day 14 post-challenge.
Splenocytes and dLNs cells were stained with anti-CD3, anti-CD90.2, anti-CD4, anti-CD62L and anti-CD44 antibodies conjugated with different
fluorochromes and CD90.2+ (Thy1.2+) cells were analyzed by flow cytometry. The expression of CD44 and CD62L on donor T cell subsets (B). Data
presented are representative of 2 independent experiments (n = 4–5 mice per group) with similar results.
doi:10.1371/journal.pone.0066058.g004
Figure 5. lpg22 L. majormediated protection is not associated with a strong DTH response. C57BL/6 mice infected with WT and lpg22 L.
major (.16 wks) were challenge with 5 million WT parasites in their contralateral footpad and delayed DTH response was measured 72 hr post-
challenge (A). After 3 wk post challenge, mice were sacrificed and parasite burden was determined (B). In some experiments, CD3+ T cells were
purified from spleens of WT or lpg2-L. major-infected mice and adoptively transferred into naı¨ve mice that were then challenged with virulent L.
major. Three weeks after challenge, mice were sacrificed to determine parasite burden (C). Data presented are representative of 4 (A and B) and 2
independent experiments (n = 3–5 mice per group) with similar results.
doi:10.1371/journal.pone.0066058.g005
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expression, the percentage of TNF-expressing CD4+ T cells from
lpg2- infected mice was comparable to those from WT-infected
mice (Figure 7A) and these cells produced similar amounts of
TNF in cultures (Figure 7B). Interestingly, the majority (.55%)
of cytokine-producing cells in WT-infected mice co-expressed
IFN-c and TNF, suggesting that polyfunctional cells predominate
in mice infected with WT but not in those infected with lpg22
parasites. However, treatment of lpg2-infected mice with Embrel
(soluble TNFR-Ig to block binding of TNF to its cellular receptors)
prior to and during secondary L. major challenge did not affect lpg2-
induced resistance (Figure 7C), suggesting that lpg2-induced
resistance is not mediated by TNF.
Discussion
In this study, we investigated the correlates and possible
mechanism of lpg2- mediated protection in murine cutaneous
leishmaniasis. We demonstrated that lpg2-infected mice contain
Leishmania-reactive (memory) cells that rapidly proliferate and
produce effector cytokines (IFN-c and TNF) in response to
Leishmania antigen stimulation in vivo and in vitro. However, lpg2-
parasites were less effective than WT parasites in inducing and/or
maintaining Leishmania-specific memory T cells. Nevertheless,
memory T cells generated by lpg2- parasites were capable of
mediating comparable protection against virulent L. major chal-
lenge, suggesting that lpg2–induced memory cells are qualitatively
and functionally comparable to those induced by WT parasites.
Depletion and neutralization studies with mAbs demonstrated that
akin to WT parasites, lpg2- L. major-mediated resistance was
strongly dependent on IFN-c, but independent of CD8+ T cells.
Because of its critical role in resistance to intracellular
pathogens, the production of IFN-c by T cells is widely used as
a parameter for assessing vaccine efficiency [33–35]. However, our
in vitro and in vivo data demonstrated that cells from lpg2-infected
mice produced significantly less IFN-c, yet these mice were
strongly protected against virulent L. major challenge. These
observations suggest that other factors contribute to secondary
immunity against virulent L. major challenge in lpg2- infected mice.
Apart from IFN-c, tumor necrosis factor (TNF) has also been
shown to play important role in protective immunity against
leishmaniasis [36,37]. Indeed, the frequency of TNF-producing
cells from lpg2-infected mice was comparable to those from WT-
infected controls (Figure 7A and 7B). Neutralization of TNF
signaling did not affect resistance of lpg22infected mice to virulent
L. major challenge, suggesting that TNF does not compensate the
defective IFN-c production in lpg2- infected mice. Interestingly,
TNF neutralization enhances parasite control in lpg2- L. major-
infected mice following virulent L. major challenge. This apparent
paradox may be related to reduced inflammation following TNF
neutralization and consequent reduction in macrophage recruit-
ment, which would reduce the number of cells available for
parasites to infect.
Although a robust IFN-c response is important for primary and
secondary resistance to L. major [38,39], recent studies suggest that
other factors distinct from the magnitude of IFN-c response might
Figure 6. Protection in lpg2-infected mice is dependent on IFN-c but is independent of CD8+ T cells. C57BL/6 mice were infected in the
right footpad with WT and lpg22 L. major and after 16 weeks, challenged with virulent L. major in the left footpads. Some mice were treated with
anti-IFN-c or anti-CD8 mAb (1 mg/ml) 24 hr prior to challenge and once weekly for additional 3 weeks. At 3 weeks post-challenge, lesion sizes (A, C)
were determined and mice were sacrificed and parasite burdens (B, D) in the challenged footpads were determined. Data presented are
representative of 2–3 independent experiments (n = 3–5 mice per group) with similar results.
doi:10.1371/journal.pone.0066058.g006
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play a more dominant role in regulating the outcome of infection
with L. major. For example, despite the presence of strong IFN-c
response, L. major clone SD (MHOM/SN/74/SD) induces chronic
non-healing lesions in C7BL/6 mice that is resolved only after
blockade of IL-10 or depletion of CD4+CD25+ Tregs [40]. In
addition, impaired Treg expansion in p110d deficient mice (and
not enhanced IFN-c response) contributed to the hyper-resistance
of these mice to L. major infection [41]. These observations suggest
that in the absence of Treg activation, low levels of IFN-c can
efficiently activate macrophages leading to effective intracellular
parasite killing in vivo. However, we did not find any difference in
the percentage or absolute numbers of Tregs in both spleens and
dLNs of WT and lpg2-infected mice (data not shown), suggesting
that lower activation of Tregs does not account for the effective
primary and/or secondary immunity in lpg2- L. major infected mice
in the presence of lower IFN-c response. Interestingly, we found
that both primary [12] and secondary (Figure 2E) infections with
lpg22 L. major result in suppressed IL-10 response. It is conceivable
that akin to L. major infection in p110d deficient mice [41] and
infection with L. major clone SD [40], the low IL-10 response could
permit low levels of IFN-c to more efficiently activate macro-
phages leading to effective parasite killing in vivo. Thus, although
lpg2- L. major-infected mice also produce significantly less IFN-c, it
is conceivable that low levels of IFN-c may be more efficient at
activating macrophages for more efficient parasite control when
IL-10 levels are also correspondingly low. In line with this, we
found that neutralization of IFN-c abolished lpg2-induced
immunity, suggesting that this low level of IFN-c is nonetheless
required for effective parasite control following secondary virulent
challenge.
The development of Leishmania vaccine is a global public health
priority because of the enormous morbidity and mortality
associated with the disease. Unfortunately, there is currently no
clinical approved vaccine for human cutaneous leishmaniasis
[42,43]. Interestingly, recovery from natural or experimental
infection leads to long-lasting protective immunity against re-
infection, an observation that formed the basis for leishmanization
still practiced in many countries today [44]. However, the
significant morbidity associated with this practice has hampered
its acceptance as a vaccination strategy. To overcome these
problems, a number of live attenuated mutant parasites have been
generated [11,13,45–47]. lpg2- parasites have several advantages
as a potential live-attenuated vaccine because it does not cause
disease in most cases even in the highly immunocompromised
(SCID) mice [12]. Although a revertant line of lpg2- parasites has
been described previously [19], we have yet to detect revertant line
in our studies using C57BL/6 mice, suggesting that this may either
be a very rare event restricted to the highly susceptible BALB/c
mice or due to latent infections or differences in gut microflora
resulting from differences in housing environments, a factor that
has been shown to affect infection outcome even in animals with
same genetic background [48–50]. In addition, altered microflora
in mice from different vendors (JAX versus The University of
Manitoba Central Animal Care Services [originally derived from
Charles River, Montreal, Canada]) might also account for the
differences from our previous observation regarding the require-
ment of CpG as adjuvant for generating protective immunity
following vaccination with lpg2- parasites [27]. Indeed, Dr
Beverley’s lab has recently completed a sequence comparison of
our strain with theirs (where reversion has been observed) and
preliminary analysis show that both strains are genetically the
same (i.e. still lack the LPG2 gene), further implicating environ-
mental and/or epigenetic factors as the primary cause of these
differences. Furthermore, similar to WT mice, lpg2- parasites
persist indefinitely in vaccinated mice [13], which eliminates the
need for repetitive inoculations. Lastly, lpg2- parasites protect
vaccinated host against virulent challenge without inducing
‘‘nasty’’ DTH response. We refer DTH as being ‘‘nasty’’ because
a huge vaccination-induced swelling (DTH response) on the face
following a bite from an infected sandfly would be undesirable.
Overall, our results show that despite poor DTH and IFN-c
recall responses, lpg2- L. major parasites induced protective
immunity in both BALB/c and C57BL/6 mice is qualitatively
comparable to those of WT parasites. We hypothesize that the
excellent protection observed in these mice is related to more
efficient IFN-c activity in the presence of low IL-10 response. Our
findings lend support for the consideration of lpg2- parasites as live-
attenuated vaccine or leishmanization candidates against cutane-
ous leishmaniasis, particularly in parts of the world where
leishmanization is still practiced with virulent parasites. This
would at least reduce the morbidity associated with using virulent
organisms for leishmanization since lpg2- parasites do not cause
any disease. We are currently examining the pathogenesis of lpg2-
parasites in non-human primates in order to determine whether
infection with this avirulent mutant parasite could also confer
protection against virulent challenge.
Figure 7. Resistance in lpg22 L. major-infected mice is not dependent of TNF. CD3+ spleen cells from WT- and lpg22 L. major-infected mice
were stimulated in vitro with infected BMDCs for 24 hr and assessed for IFN-c and TNF expression by flow cytometer. The culture supernatant fluids
were assayed for TNF by ELISA (B). Infected mice were treated with TNFR-Ig (Embrel) 24 hr prior to challenge and further treated once weekly for
additional 2 weeks. After 3 weeks mice were sacrificed and parasite burden was determined (C). Data presented are representative of 2 independent
experiments (n = 3–5 mice per group) with similar results.
doi:10.1371/journal.pone.0066058.g007
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Supporting Information
Figure S1 Impaired IL-4 and IL-10 recall response by
spleen cells from lpg2- infected mice. C57BL/6 mice were
infected with WT and lpg2- L. major and after 16 weeks, mice were
sacrificed, the spleen cells were restimulated in vitro with SLA for
72 hr and the frequency of IL-4- (A) and IL-10 (B)-producing cells
was determined by flow cytometry.
(TIF)
Figure S2 lpg2- infected mice are not impaired in their
TNF recall response. C57BL/6 mice were infected with WT
and lpg2- L. major and after 16 weeks, mice were sacrificed, the
spleen cells were restimulated in vitro with infected BMDCs for
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